Dimensional Fund Advisors
LTRN icon

Dimensional Fund Advisors’s Lantern Pharma LTRN Stock Holding History

Dimensional Fund Advisors’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$69.7K Sell
16,725
-21,335
-56% -$62.5K ﹤0.01% 3167
2026
Q1 		$52.1K Sell
38,060
-1,050
-3% -$2.94K ﹤0.01% 3175
2025
Q4 		$119K Sell
39,110
-1,034
-3% -$3.85K ﹤0.01% 3137
2025
Q3 		$175K Sell
40,144
-796
-2% -$3.32K ﹤0.01% 3134
2025
Q2 		$129K Buy
40,940
+3,457
+9% +$11.7K ﹤0.01% 3162
2025
Q1 		$133K Buy
37,483
+934
+3% +$3.88K ﹤0.01% 3170
2024
Q4 		$117K Sell
36,549
-999
-3% -$3.42K ﹤0.01% 3228
2024
Q3 		$138K Buy
37,548
+19,135
+104% +$78.8K ﹤0.01% 3215
2024
Q2 		$86K Buy
18,413
+6,585
+56% +$39.6K ﹤0.01% 3267
2024
Q1 		$104K Hold
11,828
– – ﹤0.01% 3257
2023
Q4 		$50.6K Buy
+11,828
New +$41.7K ﹤0.01% 3345

Other funds holding LTRN

EAM
Empery Asset Management New York $86.5M AUM
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return

Dimensional Fund Advisors's LTRN Position: Q2 2026 in Review

Dimensional Fund Advisors reduced its Lantern Pharma (LTRN) stake by 56% in Q2 2026, selling an estimated $62.5K and leaving 16,725 shares worth $69.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3167.

Dimensional Fund Advisors first reported a position in LTRN in Q4 2023 and has held it in 11 quarters since. The position peaked at $175K in Q3 2025. 39 funds tracked by Wall St. Rank hold LTRN as of Q2 2026.

  • Dimensional Fund Advisors held 16,725 shares of Lantern Pharma worth $69.7K as of Q2 2026.
  • Dimensional Fund Advisors sold 21,335 Lantern Pharma shares in Q2 2026, an estimated $62.5K.
  • Lantern Pharma made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q2 2026, its #3167 holding.
  • Dimensional Fund Advisors first reported a position in Lantern Pharma in Q4 2023 and has held it in 11 quarters since.
  • Dimensional Fund Advisors's Lantern Pharma position peaked at $175K in Q3 2025.
  • 39 funds tracked by Wall St. Rank held Lantern Pharma as of Q2 2026.

Based on Dimensional Fund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.